Norton thinks that the prescribing of HER2-targeting drugs won't be improved until we understand how specific mutations influence a tumor's susceptibility and sequencing can be routinely done on ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Boehringer's zongertinib and Bayer's BAY 2927088 are in phase 3 testing for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations, and the WCLC congress gave an opportunity to ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...